Format

Send to

Choose Destination
See comment in PubMed Commons below
Invest New Drugs. 2009 Apr;27(2):120-3. doi: 10.1007/s10637-008-9145-0. Epub 2008 Jun 14.

Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer.

Author information

1
Russell H. Morgan Department of Radiology, and Radiological Sciences, Division of Vascular and Interventional Radiology, 600 North Wolfe Street, Blalock 545, Baltimore, MD 21287, USA.

Abstract

PURPOSE:

To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose.

MATERIALS AND METHODS:

Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later.

RESULTS:

3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p = 0.002). FDG uptake did not significantly decrease in normal tissues after treatment.

CONCLUSION:

Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.

PMID:
18553054
DOI:
10.1007/s10637-008-9145-0
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center